MX2021012277A - Agonista multireceptor y uso medico del mismo. - Google Patents

Agonista multireceptor y uso medico del mismo.

Info

Publication number
MX2021012277A
MX2021012277A MX2021012277A MX2021012277A MX2021012277A MX 2021012277 A MX2021012277 A MX 2021012277A MX 2021012277 A MX2021012277 A MX 2021012277A MX 2021012277 A MX2021012277 A MX 2021012277A MX 2021012277 A MX2021012277 A MX 2021012277A
Authority
MX
Mexico
Prior art keywords
receptor
receptor agonist
medical use
glp
insulin
Prior art date
Application number
MX2021012277A
Other languages
English (en)
Inventor
Rudi Bao
Xiao Liu
Xiaolei Wang
Lei Wang
Haiqing Hua
Fangzhou Wu
Ran Wu
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of MX2021012277A publication Critical patent/MX2021012277A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una serie de composiciones farmacéuticas que contienen compuestos agonistas duales de polipéptidos y sales farmacéuticamente aceptables de los mismos, en donde los mismos tienen efectos agonistas duales en un receptor de péptido similar a glucagón tipo 1 (GLP-1) humano y un receptor de polipéptido insulinotrópico dependiente de glucosa (GIP) de sangre humana, y se pueden utilizar para tratar diabetes no dependiente de insulina, diabetes insulinodependiente, obesidad y otras enfermedades relacionadas.
MX2021012277A 2019-04-11 2020-04-10 Agonista multireceptor y uso medico del mismo. MX2021012277A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910290162 2019-04-11
CN201911120906 2019-11-15
PCT/CN2020/084247 WO2020207477A1 (zh) 2019-04-11 2020-04-10 Glp-1和gip受体双重激动剂化合物及其应用

Publications (1)

Publication Number Publication Date
MX2021012277A true MX2021012277A (es) 2021-11-12

Family

ID=72752204

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012277A MX2021012277A (es) 2019-04-11 2020-04-10 Agonista multireceptor y uso medico del mismo.

Country Status (11)

Country Link
US (1) US20220168396A1 (es)
EP (1) EP3954701A4 (es)
JP (1) JP2022527803A (es)
KR (1) KR20210149747A (es)
CN (1) CN112351994B (es)
AU (1) AU2020256648A1 (es)
BR (1) BR112021020071A2 (es)
CA (1) CA3136163A1 (es)
MX (1) MX2021012277A (es)
TW (1) TW202104253A (es)
WO (1) WO2020207477A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021239082A1 (zh) * 2020-05-29 2021-12-02 北京拓界生物医药科技有限公司 Glp-1和gip受体双重激动剂化合物及其应用
TWI801942B (zh) * 2020-07-22 2023-05-11 丹麥商諾佛 儂迪克股份有限公司 適用於口服的glp-1及gip受體共促效劑
EP4222176A4 (en) 2020-09-30 2024-02-28 Beijing QL Biopharmaceutical Co., Ltd. POLYPEPTIDE CONJUGATES AND METHODS OF USE
CN114617956B (zh) * 2020-12-10 2023-10-03 江苏中新医药有限公司 一种高效降糖的蛋白质药物
US20240150425A1 (en) * 2021-03-25 2024-05-09 Brightgene Bio-Medical Technology Co., Ltd. Gip and glp-1 dual receptor agonist, pharmaceutical composition, and use
CN115124602B (zh) * 2021-03-25 2024-01-26 博瑞生物医药（苏州）股份有限公司 Gip和glp-1的双受体激动剂、药物组合物及用途
JP2024522196A (ja) * 2021-06-09 2024-06-11 ザ スクリプス リサーチ インスティテュート 長時間作用型デュアルｇｉｐ／ｇｌｐ－１ペプチドコンジュゲートおよび使用方法
CN115521368B (zh) * 2021-06-25 2024-08-23 江苏鸿永医药技术有限公司 毒蜥外泌肽-4衍生物
EP4431522A1 (en) * 2021-11-12 2024-09-18 Fujian Shengdi Pharmaceutical Co., Ltd. Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof
MX2024006492A (es) * 2021-12-01 2024-06-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica de doble agonista de los receptores glp-1 y gip y uso de la misma.
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CN116023444B (zh) * 2022-08-12 2023-08-01 重庆宸安生物制药有限公司 一种gip和glp-1双受体激动剂多肽化合物及其应用
WO2024061310A1 (zh) * 2022-09-23 2024-03-28 博瑞生物医药（苏州）股份有限公司 一种glp-1和gip双受体激动剂药物组合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2440235A1 (en) * 2009-06-11 2012-04-18 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
WO2012138941A1 (en) * 2011-04-05 2012-10-11 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
KR102002783B1 (ko) 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
EP2844669B1 (en) * 2012-05-03 2018-08-01 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
CN103861089B (zh) * 2012-12-17 2019-06-28 江苏豪森药业集团有限公司 Glp-1类似物的衍生物或其可药用盐注射液及其制备方法和用途
CN104902920A (zh) * 2012-12-21 2015-09-09 赛诺菲 作为glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂的毒蜥外泌肽-4衍生物
CN106029087A (zh) * 2013-12-20 2016-10-12 印第安纳大学研究及科技有限公司 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽

Also Published As

Publication number Publication date
US20220168396A1 (en) 2022-06-02
CN112351994B (zh) 2024-06-07
WO2020207477A9 (zh) 2020-11-26
CN112351994A (zh) 2021-02-09
WO2020207477A1 (zh) 2020-10-15
TW202104253A (zh) 2021-02-01
EP3954701A1 (en) 2022-02-16
KR20210149747A (ko) 2021-12-09
BR112021020071A2 (pt) 2021-12-14
CA3136163A1 (en) 2020-10-15
EP3954701A4 (en) 2023-09-06
AU2020256648A1 (en) 2021-11-04
JP2022527803A (ja) 2022-06-06

Similar Documents

Publication Publication Date Title
MX2021012277A (es) Agonista multireceptor y uso medico del mismo.
MY197569A (en) Gip/glp1 co-agonist compounds
Prasad-Reddy et al. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Wysham et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)
Russell‐Jones et al. Recent advances in incretin‐based therapies
Scott Linagliptin: in type 2 diabetes mellitus
Bailey et al. Treatment of type 2 diabetes: future approaches
MX2022014368A (es) Compuesto de agonista doble para receptores de glp-1 y gip y aplicacion del mismo.
Barnett et al. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy
Terauchi et al. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study
AR084558A1 (es) Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1)
MX2022009149A (es) Compuestos coagonistas de gip/glp1.
Waldrop et al. Incretin-based therapy for diabetes: what a cardiologist needs to know
Cyganek et al. Liraglutide therapy in Prader-Willi syndrome.
PH12017501662A1 (en) Treatment type 2 diabetes mellitus patients
JP2016522241A5 (es)
Pizzimenti et al. Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database.
Engel et al. Assessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metformin
MX2023009550A (es) Antagonistas del receptor del peptido-1 tipo glucagon.
Horowitz et al. DPP-4 inhibition and the known unknown
Chaplin DPP‐4/SGLT2 inhibitor combined therapy for type 2 diabetes
Kenny et al. GLP-1 receptor agonist and basal insulin co-therapy in type 2 diabetes: clinical evidence and practicalities of use
BR112021017315A2 (pt) Usos terapêuticos de dulaglutida
Chan et al. Glucagon-like Peptide-1 Agonists: What the Orthopaedic Surgeon Needs to Know
Jayasinghe et al. Combining SGLT2 inhibitor and GLP-1 agonist: exaggerated weight loss in a morbidly obese patient with type 2 diabetes